Compounda Edema weight (X ± SD mg) Inhibition ratio (%)
CMC 7.6±2.8 31.8±23.9
Aspirin 0.9±0.6 89.5±7.0c
5 3.5±2.2 64.3±23.0b
9a 1.2±1.1 87.5±11.8c
9b 2.6±1.6 78.5±13.1b
9c 1.7±1.1 86.8±9.0c
10a-α 1.9±1.5 84.5±12.1b
10a-β 2.0±1.4 81.1±15.7b
10b 1.6±1.3 86.7±10.5c
10c 1.2±0.9 90.7±7.1c
11a 2.4±1.4 82.6±11.0b
11b 1.9±1.3 85.7±9.9c
11c 1.7±0.8 86.9±6.3c
cAspirin=Positive control, CMC=Vehicle, Dose of mimetic peptides derivatives=10 μmol/kg, dose of aspirin = 100 mg/kg; n = 12.
bCompared to CMC p<0.01.
cCompared to CMC p<0.01, Compared to 5 p<0.05.
Table 2: Anti-inflammatory activities of glucosamine mimetic peptides derivatives determined using an xylene-induced ear edema model.